These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 15324473)

  • 21. [Leishmania infantum/HIV co-infection: cutaneous lesions following treatment of visceral leishmaniasis].
    Catorze G; Alberto J; Afonso A; Vieira R; Cortes S; Campino L
    Ann Dermatol Venereol; 2006 Jan; 133(1):39-42. PubMed ID: 16495850
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Post-kala-azar dermal leishmaniasis (PKDL): the first case report from Nepal.
    Karki P; Koirala S; Parija SC; Sethi M; Das ML
    Southeast Asian J Trop Med Public Health; 2003 Mar; 34(1):22-3. PubMed ID: 12971510
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Post-kala-azar dermal leishmaniasis: recent developments.
    Singh S; Sharma U; Mishra J
    Int J Dermatol; 2011 Sep; 50(9):1099-108. PubMed ID: 22126871
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
    Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
    J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.
    Rihl M; Stoll M; Ulbricht K; Bange FC; Schmidt RE
    J Infect; 2006 Jul; 53(1):e25-7. PubMed ID: 16274744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Leishmaniasis chemotherapy--challenges and opportunities.
    Croft SL; Olliaro P
    Clin Microbiol Infect; 2011 Oct; 17(10):1478-83. PubMed ID: 21933306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adaptation of Leishmania donovani to cutaneous and visceral environments: in vivo selection and proteomic analysis.
    McCall LI; Zhang WW; Dejgaard K; Atayde VD; Mazur A; Ranasinghe S; Liu J; Olivier M; Nilsson T; Matlashewski G
    J Proteome Res; 2015 Feb; 14(2):1033-59. PubMed ID: 25536015
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Short communication: post-kala-azar dermal leishmaniasis--an appraisal.
    Ramesh V; Singh R; Salotra P
    Trop Med Int Health; 2007 Jul; 12(7):848-51. PubMed ID: 17596251
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reactivity of various leishmanial antigens in a direct agglutination test and their value in differentiating post-kala azar dermal leishmaniasis from leprosy and other skin conditions.
    El Harith A; Chowdhury S; Al-Masum A; Semião-Santos S; Das PK; Akhter S; Vetter JC; Haq I
    J Med Microbiol; 1996 Feb; 44(2):141-6. PubMed ID: 8642576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Post-kala-azar dermal Leishmaniasis in two different clinical contexts.
    Barroso DH; Silva CE; Perdigao e Vasconcelos AC; Cavalcanti SM; Brito ME; Medeiros AC
    An Bras Dermatol; 2015; 90(3 Suppl 1):108-10. PubMed ID: 26312689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of a species-specific PCR assay for detection of Leishmania donovani in clinical samples from patients with kala-azar and post-kala-azar dermal leishmaniasis.
    Salotra P; Sreenivas G; Pogue GP; Lee N; Nakhasi HL; Ramesh V; Negi NS
    J Clin Microbiol; 2001 Mar; 39(3):849-54. PubMed ID: 11230394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Post-kala-azar dermal leishmaniasis (PKDL), HIV and pulmonary tuberculosis.
    Das VN; Pandey K; Verma N; Bimal S; Lal CS; Singh D; Das P
    Natl Med J India; 2010; 23(2):88-9. PubMed ID: 20925205
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Post-kala-azar dermal leishmaniasis manifestation in a Mediterranean immunosuppressed patient: a rare incident.
    Panou E; Marinos L; Piperaki E; Migkou M; Stratigos AJ; Nikolaou V
    Clin Exp Dermatol; 2023 Jul; 48(7):834-836. PubMed ID: 36929204
    [No Abstract]   [Full Text] [Related]  

  • 34. Post-kala-azar dermal leishmaniasis caused by Leishmania infantum in an immunocompetent patient.
    Sánchez-Albisua B; Polimón I; Pérez-Tato B; Marinero S; Fernández-López P
    Int J Dermatol; 2013 Jul; 52(7):897-9. PubMed ID: 23675968
    [No Abstract]   [Full Text] [Related]  

  • 35. AmBisome for Kala-azar and Post-kala-azar Dermal Leishmaniasis: An Essential Option but Not a Universal Solution.
    Islam S
    Clin Infect Dis; 2019 Jun; 69(1):189. PubMed ID: 30561535
    [No Abstract]   [Full Text] [Related]  

  • 36. Cutaneous and mucocutaneous leishmaniasis: Clinical perspectives.
    Handler MZ; Patel PA; Kapila R; Al-Qubati Y; Schwartz RA
    J Am Acad Dermatol; 2015 Dec; 73(6):897-908; quiz 909-10. PubMed ID: 26568335
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Visceral leishmaniasis in the New World & Africa.
    Berman J
    Indian J Med Res; 2006 Mar; 123(3):289-94. PubMed ID: 16778311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypopigmented post-kala-azar dermal leishmaniasis.
    Ramesh V; Ramam M; Singh R; Salotra P
    Int J Dermatol; 2008 Apr; 47(4):414-6. PubMed ID: 18377613
    [No Abstract]   [Full Text] [Related]  

  • 39. Post-Kala-Azar dermal leishmaniasis in an HIV-1-infected woman: recovery after amphotericin B following failure of oral miltefosine.
    Guffanti M; Gaiera G; Bossolasco S; Ceserani N; Ratti D; Cinque P; Salmaso F; Gianotti N; Lazzarin A
    Am J Trop Med Hyg; 2008 Nov; 79(5):715-8. PubMed ID: 18981510
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Post-kala-azar dermal leishmaniasis manifesting after initiation of highly active anti-retroviral therapy in a patient with human immunodeficiency virus infection.
    Gilad J; Borer A; Hallel-Halevy D; Riesenberg K; Alkan M; Schlaeffer F
    Isr Med Assoc J; 2001 Jun; 3(6):451-2. PubMed ID: 11433642
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.